Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. ( (JP:4882) ) has provided an update.
Perseus Proteomics Inc. reported its financial results for the first quarter ending June 30, 2025, showing a slight increase in net sales to 23 million yen, but continued to operate at a loss with an operating income of negative 218 million yen. The company’s financial position weakened slightly, with total assets decreasing to 1,654 million yen and a shareholders’ equity ratio of 71.1%. Despite these challenges, the company maintains its focus on its core operations without providing a financial forecast for the fiscal year ending March 31, 2026, due to uncertainties in making rational predictions.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. operates in the biotechnology industry, focusing on the development and commercialization of antibody-based therapeutics. The company is listed on the Tokyo Stock Exchange and is engaged in advancing its research and development efforts to create innovative solutions for unmet medical needs.
Average Trading Volume: 429,442
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.99B
Find detailed analytics on 4882 stock on TipRanks’ Stock Analysis page.